Syntimmune Lands $8,000,000 Series A Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=249d0be3-09de-46a9-ab52-9a8d8e474c54 - Date
11/21/2016 - Company Name
Syntimmune - Mailing Address
257 Park Avenue South 15th Floor New York, NY 10010 USA - Company Description
Founded in 2013, Syntimmune is the world’s leader in the biology of the neonatal Fc receptor (FcRn). Helmed by the most recognized experts in its field, Syntimmune is positioned to rapidly advance breakthrough therapies which co-opt this unique target. - Website
http://www.syntimmune.com - Transaction Type
Venture Equity - Transaction Amount
$8,000,000 - Transaction Round
Series A - Proceeds Purposes
Proceeds purposes were not disclosed. - M&A Terms
- Venture Investor
Apple Tree Partners - Venture Investor
Baxalta Ventures - Venture Investor
Partners Innovation Fund
